Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s154, 2023. DOI: 10.25251/skin.7.supp.154. Disponível em: https://skin.dermsquared.com/skin/article/view/1980. Acesso em: 18 apr. 2025.